obexelimab
obexelimab: sourced relationships with 2 companies · 4 clinical trials tracked.
obexelimab evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about obexelimab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Xencor Inc (XNCR) immunoglobulin G4-related disease (IgG4-RD); warm autoimmune… | Phase 3 |
| Zenas BioPharma, Inc. (ZBIO) Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Rela… | Phase 3 |
Clinical Trial Registry Records (4)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus
Primary endpoint: Primary Outcome Measure
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Relapsing Multiple Sclerosis
Primary endpoint: Cumulative number of new GdE T1 hyperintense lesions
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Primary endpoint: Safety and Dose Confirmation Run-in Period (SRP)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)
Primary endpoint: Primary outcome measure
Frequently asked questions
Which companies have sourced relationships with obexelimab?
obexelimab has dated SEC/FDA relationship records for Xencor Inc, Zenas BioPharma, Inc..
How many clinical trials involve obexelimab?
BioSniper tracks 4 clinical trials involving obexelimab.